ABSTRACT OBJECTIVES This study explored the association of vascular hormones with myocardial recovery and clinical outcomes in peripartum cardiomyopathy (PPCM).
P eripartum cardiomyopathy (PPCM) is charac-
terized by the development of heart failure late in pregnancy or in the months after delivery (1) . Incidence varies geographically and in the Unites States is estimated at 1 in 1,000 to 4,000 live births (2) (3) (4) (5) (6) . Presentation, clinical course, and outcomes are heterogeneous and can be associated with significant morbidity and mortality (1) . In a recent prospective, multi-center study of 100 women with PPCM
(IPAC [Investigations in Pregnancy Associated
Cardiomyopathy]), 13% of patients suffered major events or had persistent severe cardiomyopathy (7) .
Factors associated with poorer outcomes include left ventricular (LV) dilation, severely depressed LV systolic function, black race, later presentation, and greater body mass index (7) (8) (9) (10) .
The etiology of PPCM is unknown. Suggested causes include genetic predisposition, hormonal abnormalities, abnormal immune response, and inflammation (11, 12) . Recently, it has been proposed that biological mediators with hemodynamic or vascular effects that are produced in the pregnant or peripartum state may play a role in the pathogenesis of PPCM (13) (14) (15) . One of these factors is relaxin-2, a hormone produced in the corpus luteum of the ovary and in the heart (16, 17) . Relaxin-2 increases during pregnancy with hemodynamic and vasoactive effects, including increased cardiac output, plasma volume, heart rate, and renal blood flow and lower vascular resistance (18) . In addition, relaxin-2 has antiinflammatory, angiogenic, and antifibrotic properties (16) . Both the vasodilatory and angiogenic effects of relaxin-2 are mediated in part by vascular endothelial growth factor (VEGF) (19, 20) , which may exert a protective effect in heart failure of multiple etiologies (21) . This understanding has led to investigation of relaxin as a therapeutic target in heart failure (22) and raises the possibility of a role in treatment of PPCM.
Another biological factor proposed to contribute to PPCM is prolactin, a pituitary hormone that is secreted in the peripartum period and stimulates lactation (23) . Under conditions of oxidative stress, prolactin is cleaved proteolytically to a 16-kDa fragment that has deleterious effects on endothelial cells and promotes inflammation and fibrosis. Higher levels of this angiostatic fragment, and the resulting angiogenic imbalance in the myocardium, have been hypothesized to play a role in the pathophysiology of PPCM (24). Another anti-angiogenic factor released from the placenta and endothelial cells in mid to late pregnancy is soluble fms-like tyrosine kinase 1 (sFlt1 or VEGF receptor 1). sFlt1 peaks at delivery and inhibits the activity of VEGF, leading to endothelial dysfunction and further angiogenic imbalance (14, 25) .
Increased levels of sFlt1 may play an important role in the development of PPCM in some women (14, 15) , and recent data suggest that therapy targeting these pathways can rescue mouse models of PPCM (14, 26 Given that relaxin-2 levels were predominantly increased in subjects presenting in the first quartile (0 to 11 days, n ¼ 25), we repeated the previous analysis specifically in this subset presenting early post-partum. GLM analysis comparing 2 month LVEF by tertiles of relaxin-2 levels (lowest, <7.0; intermediate, 7.0 to 22.0; highest, >22 pg/ml) demonstrated that the association between relaxin-2 and the 2-month LVEF was more pronounced and remained significant (p ¼ 0.02) ( Figure 2B ).
In the entire cohort, higher relaxin-2 levels were also associated with smaller LV systolic diameter (A) Relaxin-2 levels (pg/ml) were significantly higher in women presenting in the first quartile (0 to 11 days) compared with subjects presenting in the latter 3 quartiles (12 to 95 days) (p ¼ 0.0043). (B) Prolactin levels (ng/ml) were significantly higher in women presenting in the first quartile compared with subjects presenting in the latter 3 quartiles (p < 0.00001). (C) Soluble fms-like tyrosine kinase 1 (soluble Flt1) levels (pg/ml) were significantly higher in women presenting in the first quartile compared with subjects presenting in the latter 3 quartiles 
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These data also help to explain why pre-eclampsia and multiple gestations have been observed to be risk factors for the development of PPCM (27, 28) .
The source of sFlt1 in PPCM subjects presenting late is not known, but placental remnants and other circulating cells have been postulated (29, 30) . Our findings suggest a potential role for sFlt1 in risk stratification for patients presenting with PPCM.
The number of events in our study was small, however, and larger cohorts of PPCM will be needed to define the independent prognostic power 
CONCLUSIONS
In the IPAC cohort, higher relaxin-2 levels, particularly when obtained early post-partum, were associated with early myocardial recovery and a higher LVEF at 2 months. In contrast, increased sFlt1 levels were associated with higher NYHA functional class and a greater risk of major adverse events. These findings support the concept that PPCM is, at least in part, a disorder of vascular homeostasis and suggest that these biomarkers may not only assist in the determination of prognosis in PPCM, but also serve as targets for future therapy. 
